Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 167

Results For "INST"

3147 News Found

USFDA Advisory Committee votes  n Lynparza plus Abiraterone and Prednisone  for prostate cancer
Drug Approval | May 03, 2023

USFDA Advisory Committee votes n Lynparza plus Abiraterone and Prednisone for prostate cancer

The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients


IMCD Colombia acquires pharma API distributor Allianz
Supply Chain | May 03, 2023

IMCD Colombia acquires pharma API distributor Allianz

Allianz is ISO 9001:2015 certified and INVIMA certified for storage, sampling, dispensation, and distribution of APIs to the Colombian market


Healthium Medtech appoints Prashant Krishnan as Global Business Head for Advanced Wound Care and Surgery
People | May 02, 2023

Healthium Medtech appoints Prashant Krishnan as Global Business Head for Advanced Wound Care and Surgery

The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis


Kokilaben Hospital launches dedicated Hereditary Cancer Clinic
Healthcare | May 01, 2023

Kokilaben Hospital launches dedicated Hereditary Cancer Clinic

Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care


IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr
News | May 01, 2023

IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr

Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22


Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr
News | April 30, 2023

Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr

Specialty Chemicals grew 38% YoY for FY23


TPAG organizes Thalassemia & SCD prevention discussion
News | April 29, 2023

TPAG organizes Thalassemia & SCD prevention discussion

The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally


Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
News | April 28, 2023

Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr

Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects


Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData
News | April 28, 2023

Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData

Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.